Bakhtar Bioshimi Co   Report issue

For profit Phase 3
Founded: Tehran Iran (Islamic Republic of) (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
2016
NCT02705534
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

ledipasvir (Harvoni) (1 trial)

ribavirin (virazole) (1 trial)

sofosbuvir (sovaldi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Liver Cirrhosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3